Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy

Bekkering, Frank C.; Brouwer, Johannes T.; Leroux‐Roels, Geert; Vlierberghe, Hans Van; Elewaut, André; Schalm, Solko W.

doi:10.1016/s0168-8278(98)80343-7

Cited by 77 publications

(51 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who gain SVR have cleared HCV RNA from serum by 2 weeks after the treatment start [19] . HCV RNA decreased by 3 logs within the first 4 weeks of treatment in all patients who have accomplished SVR [20,21] ; decreases in HCV RNA were almost identical at 1 and 3 months, however [22] .…”

Section: Discussionmentioning

confidence: 99%

Prediction of Response to Pegylated Interferon and Ribavirin in Hepatitis C by Polymorphisms in the Viral Core Protein and Very Early Dynamics of Viremia

Akuta¹,

Suzuki²,

Kawamura³

et al. 2007

Intervirology

View full text Add to dashboard Cite

Objective: To evaluate power of amino acid polymorphisms in core protein of hepatitis C virus (HCV) for predicting sustained virological response (SVR) to pegylated interferon (Peg-IFN)/ribavirin, when they were combined with virological response. Methods: Peg-IFN/ribavirin was given to 118 patients infected with HCV genotype 1b in high viral loads. Amino acid polymorphisms (Arg70 vs. Gln70 and Leu91 vs. Met91) in combination with on-treatment virological responses were correlated with SVR. Results: End-of-treatment response (ETR) was achieved in 71% and SVR in 47% of the 118 patients. In multivariate analysis, Arg70 and Leu91, and higher ribavirin dose were independently associated with ETR. In patients with Gln70 and/or Met91, SVR was more frequent in those with than without prompt virological response (PVR) for a decrease in viral load ≧1.0 log by 48 h. Specificity in predicting patients without ETR and SVR, in combination with core polymorphisms, was not different between PVR and early virological response at 12 weeks. Conclusion: Core polymorphisms combined with PVR would be useful in promptly identifying the patients who will not respond to Peg-IFN/ribavirin, thereby avoiding unrewarding side effects and high costs.

show abstract

Section: Discussionmentioning

confidence: 99%

Prediction of Response to Pegylated Interferon and Ribavirin in Hepatitis C by Polymorphisms in the Viral Core Protein and Very Early Dynamics of Viremia

Akuta¹,

Suzuki²,

Kawamura³

et al. 2007

Intervirology

View full text Add to dashboard Cite

show abstract

“…We performed quantitation of serum HCV RNA levels by a central laboratory using multicycle reverse-transcription (RT)-PCR (SuperQuant, National Genetics Institute [NGI], Culver City, CA) as described. 14 In the event that the viral RNA level was less than the lowest limit of quantification of this assay (40 IU/ml), we performed the NGI UltraQual assay on the sample. We identified HCV genotype by PCR and DNA sequencing at Day 1 (predose), Week 4 (predose), and at the End of Treatment visit (Day 50) (LabCorp, Raritan, NJ).…”

Section: Measurement Of Hcv Rnamentioning

confidence: 99%

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus

et al. 2007

View full text Add to dashboard Cite

3) pg/ml increase (P < 0.01); and 2 5 -oligoadenylate synthetase (OAS) had a 163 (؎120.6) pmol/dl increase (P < 0.01). Decreases in HCV RNA also were dose-dependent, with the greatest group geometric mean maximum reduction of 1.69 ؎ 0.618 log 10 (P < 0.05) observed in the 0.75 mg/kg dose group. Decreases >1 log 10 were seen in 22 of 40 patients who received >1 mg CPG 10101, with 3 patients exceeding a 2.5-log 10 reduction.

show abstract

“…Nonetheless, somewhat better results have occasionally been reported in short series of patients with the use of higher doses of IFN or induction therapies based on daily administration of the drug. In the study by Beckering et al [19], sustained response was observed in 3 out of 11 patients (27%) treated with daily IFN for 5 days at a dosis of 10 MU followed by IFN 3 times a week at the same dosis until completing 4 weeks of treatment up to a total of 24 weeks at doses of 3 MU 3!/week. In another study using an initial treatment with high daily doses, a sustained rate of response was observed in 21% (9/42) [20].…”

Section: Treatment In Nonresponders To Monotherapy With Ifnmentioning

confidence: 95%

Hepatitis C: Who Should You Treat and How?

Tapias¹,

Rodés²

2002

Blood Purif

View full text Add to dashboard Cite

At present the treatment of hepatitis C virus infection (HCV) has improved because of combined treatment with interferon (IFN) and ribavirin. The association of these two drugs has obtained a positive response in 40–50% of naive patients treated. Patients with relapse after monotherapy with IFN also show positive response with combined treatment in up to about 50% of patients with HCV genotype 1b. In patients with other genotypes the response is higher (up to 70%). In nonresponders to IFN alone, the response to combined therapy was higher although there is scarce data reporting this. Similar results were achieved in cirrhotic patients. The use of pegylated IFN has shown even greater efficacy. Sustained response was greater than 50%. Lastly, triple therapy with IFN, ribavirin and amantadine has been studied in small clinical trials in nonresponders to IFN monotherapy, with controversial results since in some studies sustained response was up to 48% being less than 20% in other studies.

show abstract

Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy

Cited by 77 publications

References 9 publications

Prediction of Response to Pegylated Interferon and Ribavirin in Hepatitis C by Polymorphisms in the Viral Core Protein and Very Early Dynamics of Viremia

Prediction of Response to Pegylated Interferon and Ribavirin in Hepatitis C by Polymorphisms in the Viral Core Protein and Very Early Dynamics of Viremia

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus

Hepatitis C: Who Should You Treat and How?

Contact Info

Product

Resources

About